Loading organizations...
§ Private Profile · Tartu, Tartumaa, Estonia
Genetic testing developer creating polygenic risk score (PRS) tests for personalized cancer prevention and risk assessment.
Based in Tartu, Estonia, Antegenes develops polygenic risk score genetic tests that evaluate individual predispositions to common cancers and provide personalized clinical recommendations for disease prevention and early detection. The health-tech company operates a business-to-business model, supplying its CE-marked medical devices to oncology clinics, clinical laboratories, and public healthcare systems across European markets including the United Kingdom, Germany, and Spain. Operating with an estimated headcount of fewer than 50 employees, the university spin-off currently evaluates genetic risks for four specific conditions: breast cancer, prostate cancer, colon cancer, and skin melanoma. Antegenes has secured €2.3 million in total seed funding from a syndicate of backers that includes institutional investors EIT Health and Enterprise Estonia, alongside angel investors Timo Rein and Urmas Purde. The preventative healthcare company was officially founded in 2018 by oncologist Dr. Peeter Padrik.
Antegenes has raised $2.9M across 2 funding rounds.
Antegenes has raised $2.9M in total across 2 funding rounds.
Antegenes has raised $2.9M across 2 funding rounds. Most recently, it raised $2.4M Seed in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 2, 2022 | $2.4M Seed | Aare Kurist, Andreas Henn Otsmaa, Peep Vain, Timo Rein | Enterprise Estonia, European Institute OF Innovation And Technology | Announced |
| Nov 10, 2021 | $580K Venture Round | — | — | Announced |
Antegenes has raised $2.9M in total across 2 funding rounds.
Antegenes's investors include Aare Kurist, Andreas Henn Otsmaa, Peep Vain, Timo Rein, Enterprise Estonia, European Institute of Innovation and Technology.